标题
Immune Checkpoint Inhibitors and Atherosclerotic Vascular Events in Cancer Patients
作者
关键词
-
出版物
Frontiers in Cardiovascular Medicine
Volume 8, Issue -, Pages -
出版商
Frontiers Media SA
发表日期
2021-05-28
DOI
10.3389/fcvm.2021.652186
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Cancer patients receiving immune checkpoint inhibitor therapy are at an increased risk for atherosclerotic cardiovascular disease
- (2020) Esther Lutgens et al. Journal for ImmunoTherapy of Cancer
- Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma
- (2020) Richard S. Finn et al. NEW ENGLAND JOURNAL OF MEDICINE
- PD-1/PD-L1 in cardiovascular disease
- (2020) YunFeng Sun et al. CLINICA CHIMICA ACTA
- New Insights into Mechanisms of Immune Checkpoint Inhibitor-Induced Cardiovascular Toxicity
- (2020) Arjun Khunger et al. Current Oncology Reports
- Association Between Immune Checkpoint Inhibitors with Cardiovascular Events and Atherosclerotic Plaque
- (2020) Zsofia D. Drobni et al. CIRCULATION
- Pembrolizumab plus axitinib versus sunitinib monotherapy as first-line treatment of advanced renal cell carcinoma (KEYNOTE-426): extended follow-up from a randomised, open-label, phase 3 trial
- (2020) Thomas Powles et al. LANCET ONCOLOGY
- Antibody-Mediated Inhibition of CTLA4 Aggravates Atherosclerotic Plaque Inflammation and Progression in Hyperlipidemic Mice
- (2020) Kikkie Poels et al. Cells
- Venous and arterial thromboembolic events with immune checkpoint inhibitors: A systematic review
- (2020) Cinzia Solinas et al. THROMBOSIS RESEARCH
- T cell co-stimulation and co-inhibition in cardiovascular disease: a double-edged sword
- (2019) Karin H. Simons et al. Nature Reviews Cardiology
- Immune checkpoint inhibition alters the inflammatory cell composition of human coronary artery atherosclerosis
- (2019) Justine L. Newman et al. CARDIOVASCULAR PATHOLOGY
- Acute vascular events as a possibly related adverse event of immunotherapy: a single-institute retrospective study
- (2019) Jair Bar et al. EUROPEAN JOURNAL OF CANCER
- Is There an Interplay between Immune Checkpoint Inhibitors, Thromboprophylactic Treatments and Thromboembolic Events? Mechanisms and Impact in Non-Small Cell Lung Cancer Patients
- (2019) Federico Nichetti et al. Cancers
- Arterial thrombosis and anti-PD-1 blockade
- (2018) Céline Boutros et al. EUROPEAN JOURNAL OF CANCER
- Increased reporting of fatal immune checkpoint inhibitor-associated myocarditis
- (2018) Javid J Moslehi et al. LANCET
- Cancer immunotherapy using checkpoint blockade
- (2018) Antoni Ribas et al. SCIENCE
- Coronary Toxicities of Anti-PD-1 and Anti-PD-L1 Immunotherapies: a Case Report and Review of the Literature and International Registries
- (2018) Marion Ferreira et al. Targeted Oncology
- Immune checkpoint inhibitors and cardiovascular toxicity
- (2018) Alexander R Lyon et al. LANCET ONCOLOGY
- Hepatotoxicity and Recurrent NSTEMI While on Pembrolizumab for Metastatic Giant Cell Bone Tumor
- (2018) Jennifer M. Kwan et al. AMERICAN JOURNAL OF THE MEDICAL SCIENCES
- Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial
- (2017) Arjun V Balar et al. LANCET
- The immunology of atherosclerosis
- (2017) Anton Gisterå et al. Nature Reviews Nephrology
- Pathogenesis, Clinical Manifestations and Management of Immune Checkpoint Inhibitors Toxicity
- (2017) Alessandro Inno et al. TUMORI
- Pathogenesis, Clinical Manifestations and Management of Immune Checkpoint Inhibitors Toxicity
- (2017) Alessandro Inno et al. TUMORI JOURNAL
- 2016 European Guidelines on cardiovascular disease prevention in clinical practice
- (2016) Massimo F. Piepoli et al. EUROPEAN HEART JOURNAL
- Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial
- (2016) Roy S Herbst et al. LANCET
- Fulminant Myocarditis with Combination Immune Checkpoint Blockade
- (2016) Douglas B. Johnson et al. NEW ENGLAND JOURNAL OF MEDICINE
- Decreased Regulatory T Cells in Vulnerable Atherosclerotic Lesions: Imbalance between Pro- and Anti-Inflammatory Cells in Atherosclerosis
- (2015) Ilonka Rohm et al. MEDIATORS OF INFLAMMATION
- Programmed Cell Death-1 Deficiency Exacerbates T Cell Activation and Atherogenesis despite Expansion of Regulatory T Cells in Atherosclerosis-Prone Mice
- (2014) Clément Cochain et al. PLoS One
- Tumor Immunotherapy Directed at PD-1
- (2012) Antoni Ribas NEW ENGLAND JOURNAL OF MEDICINE
- Impairment of the Programmed Cell Death-1 Pathway Increases Atherosclerotic Lesion Development and Inflammation
- (2011) De-xiu Bu et al. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
- Cancer immunotherapy comes of age
- (2011) Ira Mellman et al. NATURE
- The immune system in atherosclerosis
- (2011) Göran K Hansson et al. NATURE IMMUNOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started